A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.

Payne H, Robinson A, Rappe B, Hilman S, De Giorgi U, Joniau S, Bordonaro R, Mallick S, Dourthe LM, Flores MM, Gumà J, Baron B, Duran A, Pranzo A, Serikoff A, Mott D, Herdman M, Pavesi M, De Santis M

Open source

DOI: 10.1002/ijc.33845
Published: 2022 Mar 1
Container: International journal of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ijc.33845,
  title = {A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.},
  author = {Payne H and Robinson A and Rappe B and Hilman S and De Giorgi U and Joniau S and Bordonaro R and Mallick S and Dourthe LM and Flores MM and Gumà J and Baron B and Duran A and Pranzo A and Serikoff A and Mott D and Herdman M and Pavesi M and De Santis M},
  year = {2022},
  journal = {International journal of cancer},
  doi = {10.1002/ijc.33845},
  url = {https://doi.org/10.1002/ijc.33845}
}

RIS

TY  - JOUR
TI  - A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
AU  - Payne H
AU  - Robinson A
AU  - Rappe B
AU  - Hilman S
AU  - De Giorgi U
AU  - Joniau S
AU  - Bordonaro R
AU  - Mallick S
AU  - Dourthe LM
AU  - Flores MM
AU  - Gumà J
AU  - Baron B
AU  - Duran A
AU  - Pranzo A
AU  - Serikoff A
AU  - Mott D
AU  - Herdman M
AU  - Pavesi M
AU  - De Santis M
PY  - 2022
JO  - International journal of cancer
DO  - 10.1002/ijc.33845
UR  - https://doi.org/10.1002/ijc.33845
ER  -

APA

H, P., A, R., B, R., S, H., U, D. G., S, J., R, B., S, M., LM, D., MM, F., J, G., B, B., A, D., A, P., A, S., D, M., M, H., M, P., & M, D. S. (2022). A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.. International journal of cancer. https://doi.org/10.1002/ijc.33845

Source records

pubmed · retrieved 2026-09-25T16:19:02.696Z